Der Immuncheckpoint PD‐1/PD‐L1: Gibt es Therapieoptionen jenseits der Antikörper?
Markella Konstantinidou(University of California, San Francisco), Alexander Dömlingꝉ(University of Groningen), Tryfon Zarganes‐Tzitzikas(University of Groningen), Tad A. Holak(Jagiellonian University), Katarzyna Magiera‐Mularz(Jagiellonian University)
Cited by 4
Related Papers
Covalent inhibitors: a rational approach to drug discovery
|RSC Medicinal Chemistry|2020|375
Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells
|Oncotarget|2017|308
PROTACs– a game-changing technology
|Expert Opinion on Drug Discovery|2019|159
Molecular glues for protein-protein interactions: Progressing toward a new dream
|Cell chemical biology|2024|139
Immune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies?
|Angewandte Chemie International Edition|2017|133